A new automated cell washer device for thawed cord blood units

Authors

  • Cesare G. Perotti,

    Corresponding author
    1. From the Immunohematology and Transfusion Service, Center for Transplant Immunology; the Legal Medicine and Toxicology Service, IRCCS Policlinico S. Matteo, Pavia, Italy.
      Cesare G. Perotti, Immunohematology and Transfusion Service, Center for Transplant Immunology, IRCCS Policlinico San Matteo, Viace Gocgi 19, Pavia, Italy; e-mail: c.perotti@smatteo.pv.it.
    Search for more papers by this author
  • Claudia Del Fante,

    1. From the Immunohematology and Transfusion Service, Center for Transplant Immunology; the Legal Medicine and Toxicology Service, IRCCS Policlinico S. Matteo, Pavia, Italy.
    Search for more papers by this author
  • Gianluca Viarengo,

    1. From the Immunohematology and Transfusion Service, Center for Transplant Immunology; the Legal Medicine and Toxicology Service, IRCCS Policlinico S. Matteo, Pavia, Italy.
    Search for more papers by this author
  • Pietro Papa,

    1. From the Immunohematology and Transfusion Service, Center for Transplant Immunology; the Legal Medicine and Toxicology Service, IRCCS Policlinico S. Matteo, Pavia, Italy.
    Search for more papers by this author
  • Loretta Rocchi,

    1. From the Immunohematology and Transfusion Service, Center for Transplant Immunology; the Legal Medicine and Toxicology Service, IRCCS Policlinico S. Matteo, Pavia, Italy.
    Search for more papers by this author
  • Paola Bergamaschi,

    1. From the Immunohematology and Transfusion Service, Center for Transplant Immunology; the Legal Medicine and Toxicology Service, IRCCS Policlinico S. Matteo, Pavia, Italy.
    Search for more papers by this author
  • Laura Bellotti,

    1. From the Immunohematology and Transfusion Service, Center for Transplant Immunology; the Legal Medicine and Toxicology Service, IRCCS Policlinico S. Matteo, Pavia, Italy.
    Search for more papers by this author
  • Andrea Marchesi,

    1. From the Immunohematology and Transfusion Service, Center for Transplant Immunology; the Legal Medicine and Toxicology Service, IRCCS Policlinico S. Matteo, Pavia, Italy.
    Search for more papers by this author
  • Laura Salvaneschi

    1. From the Immunohematology and Transfusion Service, Center for Transplant Immunology; the Legal Medicine and Toxicology Service, IRCCS Policlinico S. Matteo, Pavia, Italy.
    Search for more papers by this author

Cesare G. Perotti, Immunohematology and Transfusion Service, Center for Transplant Immunology, IRCCS Policlinico San Matteo, Viace Gocgi 19, Pavia, Italy; e-mail: c.perotti@smatteo.pv.it.

Abstract

BACKGROUND:  The current available techniques to wash out DMSO from thawed umbilical cord blood (UCB) units are based essentially on standard centrifugation in an open system with various degrees of cell loss.

STUDY DESIGN AND METHODS:  We evaluated the capacity of a new automated closed device (Cytomate, Baxter, IL) to wash out the DMSO from thawed UCB units, saving at the same time the progenitor and accessory cells in terms of CD34+ cells and MNCs. We modified the standard software of the device and calculated the cell recovery on 25 UCB units. Moreover, we set up a new gas chromatographic method to exactly detect the DMSO removal rate.

RESULTS:  To evaluate the efficiency of the Cytomate device, we considered the postthawing (prewashing) versus postwashing cell recovery. The average recovery (%) in terms of total nucleated cells was 63.30 (range, 40.12-89.00), CD34+ cells was 70.20 (range, 11.51-89.01), CD3+ cells was 61.01 (range, 28.80-87.08), CD4+ cells was 62.53 (range, 30.62-96.73), CD8+ cells was 57.4 (range, 26.87-94.72), CD19+ cells was 63.33 (range, 39.10-90.33), CD16+/56+ cells was 70.67 (range, 8.91-98.40), CFU-GM was 74.33 (range, 20.23-98.60), total CFUs was 82.34 (range, 14.83-247.12), and viability was 89.67(range, 70.74-98.30). The total working time required was, on average, 15 minutes (range, 7-20).

CONCLUSIONS:  The Cytomate device demonstrated a satisfying efficiency in cell recovery and in maintaining the clonogenic power of the UCB graft. The removal rate of DMSO was practically complete with evident advantages for the recipient. Finally, the entire manipulation performed in a closed system revealed to be safe, maintaining the sterility of the graft.

Ancillary